TheraNova’s “triple aim” is to create technologies with the potential to:
Improve outcomes for patients
Expand access to healthcare
Reduce cost for patients or payers
TheraNova pursues a rapid, highly capital-efficient process incorporating all the needed elements of medical device development in a shared services model. Since its inception in 2005, TheraNova has been able to generate clinical data within a year of funding and with less than $1MM in financing.